Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2018
At a glance
- Drugs GL ONC1 (Primary)
- Indications Peritoneal cancer
- Focus Adverse reactions
- Sponsors Genelux Corporation
- 17 May 2018 Results of the phase I, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 13 Mar 2015 Last checked against ClinicalTrials.gov record.
- 09 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.